FURU Co., Ltd. (FURU) is a corporation located in 2-3 Uguisudani-cho, Shibuya-ku, Tokyo, established in October 2006 and headed by Takashi Mishima (corporate number: 3011001049510). The last registration update was on July 1, 2019, and we conducted an absorption-type merger.
Trademarks such as PURIFUN, Legend of Legacy, and Purigraphy are registered.
Financial results for the fiscal year ending March 2024 (sales: 42,768 million yen, net income: 2,491 million yen) are posted. Employees and former employees have rated Career Change Conference at 3.2/5.0 points and Caixa's reputation at 67/100 points on various review sites.
There is no legal violation/disposition/black information posted.
Company Profile
| Corporate number | 3011001049510 |
|---|---|
| Corporate name | Furyu Co., Ltd. |
| Furigana | Furyu |
| Address/Map | 〒150-0032 2-3 Uguisudani-cho, Shibuya-ku, Tokyo |
| Stock code | 6238 |
| capital | 1,639.21 million yen *As of March 31, 2024 |
| President/Representative | Representative Director and President Takashi Mishima |
| URL | https://www.furyu.jp/ |
| telephone number | 03-5728-1761 |
| Establishment | April 1, 2007 |
| Number of employees (consolidated) | 241 men, 276 women, total 517 people *As of March 31, 2024 |
| Industry | manufacturing industry |
| Corporate number designation date | 2015/10/05 |
| Last registration update date | 2019/07/01 |
Press release & advertisement from Furyu Co., Ltd.
Flu Co., Ltd. financial history (million yen)
| year | quarter | Submission date | Sales | Operating profit | Ordinary profit | net income | comprehensive income |
|---|---|---|---|---|---|---|---|
| ending March 2015 | Full-year results | 2016/05/13 | 23,912 | 3,033 | 3,278 | 1,910 | 1,959 |
| ending March 2016 | 2Q results | 2016/11/11 | 12,287 | 2,231 | 2,253 | 1,478 | 1,438 |
| 3Q results | 2016/02/15 | 18,345 | 3,084 | 3,076 | 2,039 | 1,986 | |
| Full year revision | 2016/02/15 | 24,082 | 3,343 | 3,308 | 2,163 | – | |
| Full-year results | 2016/05/13 | 24,167 | 3,651 | 3,663 | 2,462 | 2,269 | |
| ending March 2017 | 1Q results | 2016/08/10 | 5,930 | 1,231 | 1,235 | 846 | 756 |
| 2Q forecast | 2016/05/13 | 11,630 | 1,608 | 1,604 | 1,107 | – | |
| 2Q correction | 2016/08/10 | 12,114 | 2,237 | 2,237 | 1,543 | – | |
| 2Q results | 2016/11/11 | 12,036 | 2,470 | 2,466 | 1,689 | 1,625 | |
| 3Q results | 2017/02/13 | 18,557 | 3,557 | 3,546 | 2,420 | 2,584 | |
| Full year forecast | 2016/05/13 | 25,376 | 3,680 | 3,698 | 2,555 | – | |
| Full year revision | 2016/08/10 | 25,376 | 4,032 | 4,000 | 2,777 | – | |
| Full-year results | 2017/05/12 | 24,890 | 3,920 | 3,921 | 2,798 | 2,916 | |
| ending March 2018 | 1Q results | 2017/08/09 | 5,904 | 750 | 743 | 495 | 483 |
| 2Q forecast | 2017/05/12 | 12,500 | 2,000 | 2,000 | 1,400 | – | |
| 2Q results | 2017/11/09 | 12,033 | 1,353 | 1,349 | 909 | 889 | |
| 3Q results | 2018/02/13 | 18,767 | 1,925 | 1,920 | 1,302 | 1,270 | |
| Full year forecast | 2017/05/12 | 26,500 | 4,000 | 4,000 | 2,800 | – | |
| Full year revision | 2017/11/09 | 26,000 | 3,000 | 3,000 | 2,100 | – | |
| Full-year results | 2018/05/14 | 25,383 | 2,453 | 2,474 | 1,725 | 1,642 | |
| ending March 2019 | 1Q results | 2018/08/09 | 6,124 | 741 | 740 | 499 | 519 |
| 2Q results | 2018/11/13 | 12,706 | 1,855 | 1,834 | 1,199 | 1,227 | |
| 3Q results | 2019/02/13 | 20,238 | 2,775 | 2,749 | 1,410 | 1,391 | |
| Full year forecast | 2018/05/14 | 25,000 | 2,500 | 2,500 | 1,740 | – | |
| Full year revision | 2019/02/13 | 26,800 | 3,280 | 3,270 | 1,770 | – | |
| Full-year results | 2019/05/14 | 27,134 | 3,543 | 3,531 | 1,882 | 1,817 | |
March 2020 /piece | 1Q results | 2019/08/08 | 6,234 | 711 | 710 | 549 | 524 |
| 2Q results | 2019/11/13 | 12,992 | 1,804 | 1,791 | 1,352 | 1,324 | |
| 3Q results | 2020/02/13 | 20,578 | 3,140 | 3,123 | 2,431 | – | |
| Full year forecast | 2019/05/14 | 27,600 | 3,600 | 3,600 | 2,400 | – | |
| Full year revision | 2020/02/13 | 28,000 | 3,900 | 3,850 | 3,000 | – | |
| Full-year results | 2020/05/14 | 27,431 | 3,637 | 3,656 | 3,020 | – | |
Individual for the fiscal year ending March 2021 | 1Q results | 2020/08/13 | 4,390 | 145 | 140 | 94 | – |
| 2Q results | 2020/11/12 | 10,657 | 911 | 893 | 609 | – | |
| 3Q results | 2021/02/12 | 17,809 | 1,668 | 1,649 | 1,129 | – | |
| Full year forecast | 2020/05/14 | 27,000 | 2,000 | 2,000 | 1,350 | – | |
| Full year revision | 2020/08/13 | 24,000 | 1,500 | 1,500 | 1,000 | – | |
| Full year revision | 2020/11/12 | 24,500 | 2,000 | 2,000 | 1,350 | – | |
| Full-year results | 2021/05/13 | 24,777 | 2,736 | 2,716 | 1,844 | – | |
| ending March 2022 | 1Q results | 2021/08/12 | 7,999 | 1,190 | 1,179 | 812 | 811 |
| 2Q results | 2021/11/12 | 16,728 | 2,687 | 2,694 | 1,861 | 1,868 | |
| 3Q results | 2022/02/14 | 25,801 | 3,583 | 3,584 | 2,487 | 2,443 | |
| Full year revision | 2021/05/13 | 32,000 | 3,200 | 3,200 | 2,200 | – | |
| Full year revision | 2021/08/12 | 36,000 | 3,900 | 3,900 | 2,700 | – | |
| Full-year results | 2022/05/12 | 34,058 | 3,709 | 3,707 | 2,544 | 2,577 | |
| ending March 2023 | 1Q results | 2022/08/12 | 8,142 | 679 | 639 | 416 | 509 |
| 2Q results | 2022/11/14 | 17,987 | 1,584 | 1,574 | 1,036 | 1,156 | |
| 3Q results | 2023/02/14 | 27,339 | 2,094 | 2,125 | 1,400 | 1,251 | |
| Full year forecast | 2022/05/12 | 37,000 | 3,750 | 3,750 | 2,560 | – | |
| Full year revision | 2022/08/12 | 36,600 | 2,240 | 2,240 | 1,555 | – | |
| Full-year results | 2023/05/12 | 36,400 | 2,134 | 2,179 | 1,443 | 1,324 | |
| ending March 2024 | 1Q results | 2023/08/10 | 9,974 | 1,315 | 1,262 | 840 | 981 |
| 2Q results | 2023/11/14 | 21,083 | 2,427 | 2,374 | 1,583 | 1,765 | |
| 3Q results | 2024/02/14 | 32,550 | 3,513 | 3,501 | 2,351 | 2,388 | |
| Full year forecast | 2023/05/12 | 39,000 | 2,500 | 2,500 | 1,735 | – | |
| Full year revision | 2023/11/14 | 42,000 | 3,300 | 3,300 | 2,300 | – | |
| Full year revision | 2024/02/14 | 42,000 | 3,900 | 3,900 | 2,700 | – | |
| Full-year results | 2024/05/14 | 42,768 | 3,771 | 3,735 | 2,491 | 2,714 | |
| ending March 2025 | Full year forecast | 2024/05/14 | 43,000 | 3,000 | 3,000 | 2,000 | – |
| year | quarter | Submission date | Sales | Operating profit | Ordinary profit | net income | comprehensive income |
![Medicinal hair growth agent [hair tonic glow gel]](https://companydata.tsujigawa.com/wp-content/uploads/2024/07/hair-tonic-glow-gel-pr-01-150x150.jpg)
